Imugene posts high response rates for azer-cel in early CAR T-naïve lymphoma trial

The latest update is out from Imugene ( (AU:IMU) ).

Imugene reported strong early efficacy data from the CAR T-naïve cohort of its Phase 1b basket study of azer-cel, an off-the-shelf allogeneic CAR T cell therapy for advanced B-cell cancers. The company is seeing faster enrolment in this cohort than in its earlier CAR T-relapsed DLBCL group, highlighting robust clinical interest and potential competitive differentiation.

In patients heavily pre-treated for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, azer-cel achieved a 100% overall response rate, all partial responses, in an indication where partial responses have historically underpinned regulatory approvals. The therapy also delivered an 80% overall response rate in Marginal Zone Lymphoma, including a majority of complete responses, supporting Imugene’s basket-trial strategy to prioritise the most responsive indications and potentially accelerate a capital-efficient path to registration across select B-cell malignancies.

The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.21 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is an ASX-listed, clinical-stage immuno-oncology company developing novel cancer therapies, including off-the-shelf, allogeneic CAR T cell treatments. The company focuses on advanced B-cell malignancies with significant unmet medical need, aiming to bring capital-efficient and potentially faster-to-market immunotherapies to patients.

YTD Price Performance: -35.62%

Average Trading Volume: 1,403,619

Technical Sentiment Signal: Sell

Current Market Cap: A$75.56M

See more insights into IMU stock on TipRanks’ Stock Analysis page.